Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,
Keywords: NEC, immunotherapy,
Introduction: Neuroendocrine carcinomas (NECs) are a rare subgroup of neuroendocrine neoplasms that occasionally originate from gastro-entero-pancreatic (GEP) tract. Owing to their low incidence, evidences of the effectiveness of chemotherapy are scarce. Analogously to small cell lung cancer, platinum plus etoposide (Vp16) regimens are currently the standard treatment in first-line, while little data are available on the role of second-line treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Bardasi C, Caputo F, Santini C, Cerma K, Casadei Gardini A,
Keywords: neuroendocrine carcinoma, irinotecan, survival, second line treatment, NEC, chemotherapy,
Introduction: The prognosis for pts with PD-EP-NEC is poor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: McNamara M
Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,
Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,
Introduction: Prostatic neuroendocrine carcinomas (PNECs) are rare tumors with poor prognosis. While platinum and etoposide based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, clinical-grade evidence for treatment options in second-line and beyond is very limited.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Apostolidis L, Nientiedt C, Winkler E, Stenzinger A, Duensing S,
Keywords: neuroendocrine carcinoma, prostate, chemotherapy, immunotherapy,
Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,
Keywords: Neuroendocrine Carcinoma, Temozolomide,